|
| Press Releases |
|
 |
|
| Wednesday, December 20, 2023 |
|
|
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that, OT-703 (ILUVIEN(R), fluocinolone intravitreal implant), an injectable more info >> |
|
| Thursday, August 24, 2023 |
|
|
Ocumension Therapeutics Announces 2023 Interim Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its interim results for the six months ended 30 June 2023 ("the Period") today. more info >> |
|
| Thursday, March 30, 2023 |
|
|
Ocumension Therapeutics Announces 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its annual results for the year ended 31 December 2022 today. more info >> |
|
| Monday, March 13, 2023 |
|
|
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that the Company's ordinary shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on March 13, 2023. more info >> |
|
| Tuesday, February 14, 2023 |
|
|
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, is pleased to announce that it is anticipated that the Company will record a significant increase in its revenue and gross profit for the year ended 31 December 2022 (the "Year 2022"). more info >> |
|
| Friday, February 3, 2023 |
|
|
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202 |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully. more info >> |
|
| Wednesday, February 1, 2023 |
|
|
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that OT-101 (0.01% atropine sulfate eye drop) more info >> |
|
| Monday, January 30, 2023 |
|
|
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively |
| Ocumension Therapeutics (1477.HK) is pleased to announce that Mr. Tim RUAN and Mr. WANG Chong have been appointed as Chief Financial Officer and Head of Investor Relations respectively of the Group. more info >> |
|
| Saturday, March 20, 2021 |
|
|
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results |
| The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended 31 December 2020 today. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Singapore Unveils Its First Live Painting Event Featuring ADHD Artists, Inspired by 'Collide' by Tay Guan Hin" 
Apr 23, 2024 14:28 HKT/SGT
|
|
|
EM2AI Revolutionising the Dental Industry: New AI Products Promise Transparent Treatment Plans for Patients
Apr 23, 2024 14:00 HKT/SGT
|
|
|
Vietnam: Nutifood opts for innovative SIG DomeMini on-the-go carton bottle
Apr 23, 2024 14:00 HKT/SGT
|
|
|
Citi, UBS, GS view positive on Fosun's core business-focused strategy
Apr 23, 2024 12:28 HKT/SGT
|
|
|
Indonesia Ready to Lead Water Governance Transformation at the 10th World Water Forum
Apr 23, 2024 12:00 HKT/SGT
|
|
|
(Second overseas roadshow of 2024) MGTO unveils mega roadshow and presentation seminar in Singapore this Thursday (25 April) to tap into overseas markets
Apr 23, 2024 10:00 HKT/SGT
|
|
|
Beyond Centralization: Exploring a New Era at the World Blockchain Summit
Apr 23, 2024 09:47 HKT/SGT
|
|
|
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
|
|
|
Indonesia Ready to Lead Water Governance Transformation at the 10th World Water Forum
Apr 23, 2024 06:00 HKT/SGT
|
|
|
GMG Provides Commercialisation Update on Energy Savings Coating THERMAL-XR(R)
Apr 23, 2024 02:39 HKT/SGT
|
|
|
SIFAS Festival of Arts 2024 to captivate audiences on April 27 and 28 at Esplanade - Theatres on the Bay
Apr 23, 2024 00:20 HKT/SGT
|
|
|
Molecular Farming Company to Achieve USDA Approval for Plant-Grown Animal Proteins
Apr 22, 2024 20:00 HKT/SGT
|
|
|
UK's Largest EV Show Returns for 4th Edition Driving Innovation with Policy Leaders, Product Launches, and EV Innovations
Apr 22, 2024 19:15 HKT/SGT
|
|
|
SMC Announces Marketing Agreement with Plato Technologies. Inc.
Apr 22, 2024 19:03 HKT/SGT
|
|
|
The South China Sea: A Nuanced Understanding Required
Apr 22, 2024 17:12 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
